Hydromer Selected as Key Coatings Provider for Avinger’s Image-Guided PAD Therapeutic Devices
Hydromer (HYDI:OTC) has been selected as the key coatings partner for Avinger, focusing on innovations in catheter-based systems for Peripheral Artery Disease (PAD).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Hydromer (HYDI:OTC) has been selected as the key coatings partner for Avinger, focusing on innovations in catheter-based systems for Peripheral Artery Disease (PAD). Avinger’s products utilizing Hydromer’s coatings include Pantheris®, Ocelot, and the new Tigereye™ device, enhancing performance by enabling safer and more effective treatments. Hydromer’s hydrophilic coatings are recognized as critical in advancing Avinger’s medical technologies, improving patient outcomes through reduced risk of arterial injury.
Positive
- Selected as key coatings partner for Avinger, enhancing its medical devices.
- Coatings are integral to Avinger’s innovative catheter-based products for PAD.
- Recognition from Avinger’s CEO highlights the advantages of Hydromer’s technology.
Negative
- None.
Details
News Market Reaction – HYDI
The recorded move for HYDI in the trading session of this news was +20.93%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Concord, NC, May 20, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Hydromer, Inc. (the “Company”) (HYDI:OTC) is proud to announce it has been selected as the key coatings and services partner for Avinger, Inc.’s intravascular image-guided, catheter-based systems for diagnosis and treatment of patients with Peripheral Artery Disease (PAD).
Avinger’s best-in class product lines that deploy Hydromer’s coatings include Pantheris®, the first ever image-guided atherectomy device; Ocelot, the first ever image-guided CTO crossing device; and the new Tigereye™ next generation image-guided CTO crossing device.
“Hydromer® is honored to provide our patented hydrophilic coatings and services for Avinger’s groundbreaking medical devices,” said Ravi Rangarajan, Hydromer’s VP of Sales & Marketing. “Our hydrophilic coatings play a key role enabling Avinger’s cutting-edge devices to go further, faster, and more accurately into the patient’s vasculature, while also reducing injury to the inside of patients’ arterial walls.”
“Hydromer’s hydrophilic coatings provide important advantage in our growing catheter-based image-guided treatments for PAD,” said Jeff Soinski, President and CEO of Avinger. “We appreciate the significant benefits that Hydromer’s proprietary hydrophilic coatings bring to our catheters and the long-standing partnership of the professionals at Hydromer in bringing this important technology to the market.”
About Hydromer®
Hydromer® is a leading global surface modification and coatings solutions provider. As a trusted partner to companies worldwide, our solutions add value to our clients’ products so that they can stand out in the marketplace. We are an innovation-driven, customer-centered organization with a focus on meeting our clients’ needs.
Hydromer, Inc.
800-287-5208
info@hydromer.com
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.